MET Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer
An optimal therapeutic regimen for endometrial cancer with extra-uterine metastasis is unavailable. This study aims to improve our understanding of the genomic landscape of advanced endometrial cancer and identify potential therapeutic targets. The clinical and genomic profiles of 81 patients with s...
Gespeichert in:
| Veröffentlicht in: | Cancers 2021-08, Vol.13 (16), p.4231 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 16 |
| container_start_page | 4231 |
| container_title | Cancers |
| container_volume | 13 |
| creator | Yeh, Yu-Min Wu, Pei-Ying Lin, Peng-Chan Su, Pei-Fang Hsu, Ya-Ting Hsu, Keng-Fu Shen, Meng-Ru |
| description | An optimal therapeutic regimen for endometrial cancer with extra-uterine metastasis is unavailable. This study aims to improve our understanding of the genomic landscape of advanced endometrial cancer and identify potential therapeutic targets. The clinical and genomic profiles of 81 patients with stage III or IV endometrial cancer were integrated. To identify genomic aberrations associated with clinical outcomes, Cox proportional hazard regression was used. The impacts of the genomic aberrations were validated in vitro and in vivo. The mutation status of MET, U2AF1, BCL9, PPP2R1A, IDH2, CBL, BTK, and CHEK2 were positively correlated with poor clinical outcomes. MET mutations occurred in 30% of the patients who presented with poor overall survival (hazard ratio, 2.606; 95% confidence interval, 1.167~5.819; adjusted p-value, 0.067). Concurrent MET and KRAS mutations presented with the worst outcomes. MET mutations in hepatocyte growth factor (HGF)-binding (58.1%) or kinase (16.2%) domains resulted in differential HGF-induced c-MET phosphorylation. Different types of MET mutations differentially affected tumor growth and displayed different sensitivities to cisplatin and tyrosine kinase inhibitors. MET N375S mutation is a germline variant that causes chemoresistance to cisplatin, with a high incidence in Eastern Asia. This study highlights the ethnic differences in the biology of the disease, which can influence treatment recommendations and the genome-guided clinical trials of advanced endometrial cancer. |
| doi_str_mv | 10.3390/cancers13164231 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8392057</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2566044005</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-bb8c64f62b31c5d8b0f9ebff02de1f0602f6f040482ae533f6258879adffa4a3</originalsourceid><addsrcrecordid>eNpdkcFLwzAUxoMobsydvQa8eKlLkzRNL8IYUwebeug9pGmydbTNTFLB_97WDdG9y3vwfnzve3wA3MbogZAMzZRslXY-JjGjmMQXYIxRiiPGMnr5Zx6Bqfd71BchccrSazAilJKM8GQMXjfLHG66IENlW7jyUMJ3G3QbKlnDfKedPOguVArm0m11gMY6OC8_h8slXLalbXRwA7v4MXMDroysvZ6e-gTkT8t88RKt355Xi_k6UiTjISoKrhg1DBckVknJC2QyXRiDcKljgxjChhlEEeVY6oSQnkw4TzNZGiOpJBPweJQ9dEWjS9X7dbIWB1c10n0JKyvxf9NWO7G1n4KTDKMk7QXuTwLOfnTaB9FUXum6lq22nRc4YQxRilDSo3dn6N52ru2_GyiaphnGAzU7UspZ7502v2ZiJIa0xFla5Bv2P4fi</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2564779225</pqid></control><display><type>article</type><title>MET Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Yeh, Yu-Min ; Wu, Pei-Ying ; Lin, Peng-Chan ; Su, Pei-Fang ; Hsu, Ya-Ting ; Hsu, Keng-Fu ; Shen, Meng-Ru</creator><creatorcontrib>Yeh, Yu-Min ; Wu, Pei-Ying ; Lin, Peng-Chan ; Su, Pei-Fang ; Hsu, Ya-Ting ; Hsu, Keng-Fu ; Shen, Meng-Ru</creatorcontrib><description>An optimal therapeutic regimen for endometrial cancer with extra-uterine metastasis is unavailable. This study aims to improve our understanding of the genomic landscape of advanced endometrial cancer and identify potential therapeutic targets. The clinical and genomic profiles of 81 patients with stage III or IV endometrial cancer were integrated. To identify genomic aberrations associated with clinical outcomes, Cox proportional hazard regression was used. The impacts of the genomic aberrations were validated in vitro and in vivo. The mutation status of MET, U2AF1, BCL9, PPP2R1A, IDH2, CBL, BTK, and CHEK2 were positively correlated with poor clinical outcomes. MET mutations occurred in 30% of the patients who presented with poor overall survival (hazard ratio, 2.606; 95% confidence interval, 1.167~5.819; adjusted p-value, 0.067). Concurrent MET and KRAS mutations presented with the worst outcomes. MET mutations in hepatocyte growth factor (HGF)-binding (58.1%) or kinase (16.2%) domains resulted in differential HGF-induced c-MET phosphorylation. Different types of MET mutations differentially affected tumor growth and displayed different sensitivities to cisplatin and tyrosine kinase inhibitors. MET N375S mutation is a germline variant that causes chemoresistance to cisplatin, with a high incidence in Eastern Asia. This study highlights the ethnic differences in the biology of the disease, which can influence treatment recommendations and the genome-guided clinical trials of advanced endometrial cancer.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13164231</identifier><identifier>PMID: 34439385</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Apoptosis ; Bruton's tyrosine kinase ; c-Met protein ; Cancer therapies ; Chemoresistance ; Chemotherapy ; Cisplatin ; Clinical trials ; Endometrial cancer ; Endometrium ; Estrogens ; Genomes ; Genomics ; Hepatocyte growth factor ; Medical prognosis ; Medical research ; Metastases ; Metastasis ; Mutagenesis ; Mutation ; Patients ; Phosphorylation ; Protein-tyrosine kinase ; Proteins ; Survival ; Therapeutic applications ; Therapeutic targets ; Tumors ; Uterine cancer ; Uterus</subject><ispartof>Cancers, 2021-08, Vol.13 (16), p.4231</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-bb8c64f62b31c5d8b0f9ebff02de1f0602f6f040482ae533f6258879adffa4a3</citedby><cites>FETCH-LOGICAL-c398t-bb8c64f62b31c5d8b0f9ebff02de1f0602f6f040482ae533f6258879adffa4a3</cites><orcidid>0000-0002-9424-1985 ; 0000-0002-2698-4971 ; 0000-0001-7649-2812 ; 0000-0002-8168-6125</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392057/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392057/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids></links><search><creatorcontrib>Yeh, Yu-Min</creatorcontrib><creatorcontrib>Wu, Pei-Ying</creatorcontrib><creatorcontrib>Lin, Peng-Chan</creatorcontrib><creatorcontrib>Su, Pei-Fang</creatorcontrib><creatorcontrib>Hsu, Ya-Ting</creatorcontrib><creatorcontrib>Hsu, Keng-Fu</creatorcontrib><creatorcontrib>Shen, Meng-Ru</creatorcontrib><title>MET Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer</title><title>Cancers</title><description>An optimal therapeutic regimen for endometrial cancer with extra-uterine metastasis is unavailable. This study aims to improve our understanding of the genomic landscape of advanced endometrial cancer and identify potential therapeutic targets. The clinical and genomic profiles of 81 patients with stage III or IV endometrial cancer were integrated. To identify genomic aberrations associated with clinical outcomes, Cox proportional hazard regression was used. The impacts of the genomic aberrations were validated in vitro and in vivo. The mutation status of MET, U2AF1, BCL9, PPP2R1A, IDH2, CBL, BTK, and CHEK2 were positively correlated with poor clinical outcomes. MET mutations occurred in 30% of the patients who presented with poor overall survival (hazard ratio, 2.606; 95% confidence interval, 1.167~5.819; adjusted p-value, 0.067). Concurrent MET and KRAS mutations presented with the worst outcomes. MET mutations in hepatocyte growth factor (HGF)-binding (58.1%) or kinase (16.2%) domains resulted in differential HGF-induced c-MET phosphorylation. Different types of MET mutations differentially affected tumor growth and displayed different sensitivities to cisplatin and tyrosine kinase inhibitors. MET N375S mutation is a germline variant that causes chemoresistance to cisplatin, with a high incidence in Eastern Asia. This study highlights the ethnic differences in the biology of the disease, which can influence treatment recommendations and the genome-guided clinical trials of advanced endometrial cancer.</description><subject>Apoptosis</subject><subject>Bruton's tyrosine kinase</subject><subject>c-Met protein</subject><subject>Cancer therapies</subject><subject>Chemoresistance</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Clinical trials</subject><subject>Endometrial cancer</subject><subject>Endometrium</subject><subject>Estrogens</subject><subject>Genomes</subject><subject>Genomics</subject><subject>Hepatocyte growth factor</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mutagenesis</subject><subject>Mutation</subject><subject>Patients</subject><subject>Phosphorylation</subject><subject>Protein-tyrosine kinase</subject><subject>Proteins</subject><subject>Survival</subject><subject>Therapeutic applications</subject><subject>Therapeutic targets</subject><subject>Tumors</subject><subject>Uterine cancer</subject><subject>Uterus</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkcFLwzAUxoMobsydvQa8eKlLkzRNL8IYUwebeug9pGmydbTNTFLB_97WDdG9y3vwfnzve3wA3MbogZAMzZRslXY-JjGjmMQXYIxRiiPGMnr5Zx6Bqfd71BchccrSazAilJKM8GQMXjfLHG66IENlW7jyUMJ3G3QbKlnDfKedPOguVArm0m11gMY6OC8_h8slXLalbXRwA7v4MXMDroysvZ6e-gTkT8t88RKt355Xi_k6UiTjISoKrhg1DBckVknJC2QyXRiDcKljgxjChhlEEeVY6oSQnkw4TzNZGiOpJBPweJQ9dEWjS9X7dbIWB1c10n0JKyvxf9NWO7G1n4KTDKMk7QXuTwLOfnTaB9FUXum6lq22nRc4YQxRilDSo3dn6N52ru2_GyiaphnGAzU7UspZ7502v2ZiJIa0xFla5Bv2P4fi</recordid><startdate>20210823</startdate><enddate>20210823</enddate><creator>Yeh, Yu-Min</creator><creator>Wu, Pei-Ying</creator><creator>Lin, Peng-Chan</creator><creator>Su, Pei-Fang</creator><creator>Hsu, Ya-Ting</creator><creator>Hsu, Keng-Fu</creator><creator>Shen, Meng-Ru</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9424-1985</orcidid><orcidid>https://orcid.org/0000-0002-2698-4971</orcidid><orcidid>https://orcid.org/0000-0001-7649-2812</orcidid><orcidid>https://orcid.org/0000-0002-8168-6125</orcidid></search><sort><creationdate>20210823</creationdate><title>MET Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer</title><author>Yeh, Yu-Min ; Wu, Pei-Ying ; Lin, Peng-Chan ; Su, Pei-Fang ; Hsu, Ya-Ting ; Hsu, Keng-Fu ; Shen, Meng-Ru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-bb8c64f62b31c5d8b0f9ebff02de1f0602f6f040482ae533f6258879adffa4a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Apoptosis</topic><topic>Bruton's tyrosine kinase</topic><topic>c-Met protein</topic><topic>Cancer therapies</topic><topic>Chemoresistance</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Clinical trials</topic><topic>Endometrial cancer</topic><topic>Endometrium</topic><topic>Estrogens</topic><topic>Genomes</topic><topic>Genomics</topic><topic>Hepatocyte growth factor</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mutagenesis</topic><topic>Mutation</topic><topic>Patients</topic><topic>Phosphorylation</topic><topic>Protein-tyrosine kinase</topic><topic>Proteins</topic><topic>Survival</topic><topic>Therapeutic applications</topic><topic>Therapeutic targets</topic><topic>Tumors</topic><topic>Uterine cancer</topic><topic>Uterus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yeh, Yu-Min</creatorcontrib><creatorcontrib>Wu, Pei-Ying</creatorcontrib><creatorcontrib>Lin, Peng-Chan</creatorcontrib><creatorcontrib>Su, Pei-Fang</creatorcontrib><creatorcontrib>Hsu, Ya-Ting</creatorcontrib><creatorcontrib>Hsu, Keng-Fu</creatorcontrib><creatorcontrib>Shen, Meng-Ru</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yeh, Yu-Min</au><au>Wu, Pei-Ying</au><au>Lin, Peng-Chan</au><au>Su, Pei-Fang</au><au>Hsu, Ya-Ting</au><au>Hsu, Keng-Fu</au><au>Shen, Meng-Ru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MET Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer</atitle><jtitle>Cancers</jtitle><date>2021-08-23</date><risdate>2021</risdate><volume>13</volume><issue>16</issue><spage>4231</spage><pages>4231-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>An optimal therapeutic regimen for endometrial cancer with extra-uterine metastasis is unavailable. This study aims to improve our understanding of the genomic landscape of advanced endometrial cancer and identify potential therapeutic targets. The clinical and genomic profiles of 81 patients with stage III or IV endometrial cancer were integrated. To identify genomic aberrations associated with clinical outcomes, Cox proportional hazard regression was used. The impacts of the genomic aberrations were validated in vitro and in vivo. The mutation status of MET, U2AF1, BCL9, PPP2R1A, IDH2, CBL, BTK, and CHEK2 were positively correlated with poor clinical outcomes. MET mutations occurred in 30% of the patients who presented with poor overall survival (hazard ratio, 2.606; 95% confidence interval, 1.167~5.819; adjusted p-value, 0.067). Concurrent MET and KRAS mutations presented with the worst outcomes. MET mutations in hepatocyte growth factor (HGF)-binding (58.1%) or kinase (16.2%) domains resulted in differential HGF-induced c-MET phosphorylation. Different types of MET mutations differentially affected tumor growth and displayed different sensitivities to cisplatin and tyrosine kinase inhibitors. MET N375S mutation is a germline variant that causes chemoresistance to cisplatin, with a high incidence in Eastern Asia. This study highlights the ethnic differences in the biology of the disease, which can influence treatment recommendations and the genome-guided clinical trials of advanced endometrial cancer.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34439385</pmid><doi>10.3390/cancers13164231</doi><orcidid>https://orcid.org/0000-0002-9424-1985</orcidid><orcidid>https://orcid.org/0000-0002-2698-4971</orcidid><orcidid>https://orcid.org/0000-0001-7649-2812</orcidid><orcidid>https://orcid.org/0000-0002-8168-6125</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2021-08, Vol.13 (16), p.4231 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8392057 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Apoptosis Bruton's tyrosine kinase c-Met protein Cancer therapies Chemoresistance Chemotherapy Cisplatin Clinical trials Endometrial cancer Endometrium Estrogens Genomes Genomics Hepatocyte growth factor Medical prognosis Medical research Metastases Metastasis Mutagenesis Mutation Patients Phosphorylation Protein-tyrosine kinase Proteins Survival Therapeutic applications Therapeutic targets Tumors Uterine cancer Uterus |
| title | MET Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T15%3A35%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MET%20Mutation%20Is%20a%20Potential%20Therapeutic%20Target%20for%20Advanced%20Endometrial%20Cancer&rft.jtitle=Cancers&rft.au=Yeh,%20Yu-Min&rft.date=2021-08-23&rft.volume=13&rft.issue=16&rft.spage=4231&rft.pages=4231-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13164231&rft_dat=%3Cproquest_pubme%3E2566044005%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2564779225&rft_id=info:pmid/34439385&rfr_iscdi=true |